Tag Archives: Mayo

Genetic Technologies v. Bristol Myers – 101 At Work

Posted on November 5, 2014 by Warren Woessner

In the recent memorandum opinion, the court invalidated claim 1 of U.S. Pat. No. 5,612,179, owned by Genetic Technologies, Ltd., as “impermissibly [claiming] a natural phenomenon.” (Genetic Technologies, Ltd. v. Bristol-Myers Squibb Company, C.A. No. 12-394-LPS (D. Delaware, Oct. 30, … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged Federal Circuit, Genetic Technologies, intellectual property, ip, Mayo, Myriad, Patent Law, patents, Warren Woessner | 1 Comment

101 Rejections Under the Guidelines: Mayo and Myriad “Go Viral”

Posted on September 4, 2014 by Warren Woessner

This is a guest post from Hans Sauer, Deputy General Counsel, Intellectual Property for BIO. “Recently, I set out to find real-world examples of recent rejections under the USPTO Guidance, to do my own sampling rather than rely on reported … Continue reading →

Posted in Claim Interpretation | Tagged bio, biotechnology law, biotechnology news, Federal Circuit, Hans Sauer, intellectual property, ip, Mayo, Myriad, Patent Law, patents, USPTO, Warren Woessner | 1 Comment

USPTO TRIPs over Myriad-Mayo guidance

Posted on July 31, 2014 by Warren Woessner

Timothy W. Roberts, Chartered Patent Attorney; MA (Oxon); LL.D (honoris causa, Sheffield University) Paul G. Cole, Chartered Patent Attorney; MA (Oxon); LLM, NottinghamTrent; Visiting Professor, Bournemouth University The above UK-based European Practitioners have today filed comments at the USPTO arguing … Continue reading →